150 related articles for article (PubMed ID: 34875817)
1. Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment.
Jang E; Ha J; Baek KH; Kang MI
Endocrinol Metab (Seoul); 2021 Dec; 36(6):1211-1218. PubMed ID: 34875817
[TBL] [Abstract][Full Text] [Related]
2. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
[TBL] [Abstract][Full Text] [Related]
4. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
[TBL] [Abstract][Full Text] [Related]
5. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α.
Brunetti G; Papadia F; Tummolo A; Fischetto R; Nicastro F; Piacente L; Ventura A; Mori G; Oranger A; Gigante I; Colucci S; Ciccarelli M; Grano M; Cavallo L; Delvecchio M; Faienza MF
Osteoporos Int; 2016 Jul; 27(7):2355-2365. PubMed ID: 26856585
[TBL] [Abstract][Full Text] [Related]
6. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
7. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
[TBL] [Abstract][Full Text] [Related]
8. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
[TBL] [Abstract][Full Text] [Related]
9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
Xu S; Wang Y; Lu J; Xu J
Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
[TBL] [Abstract][Full Text] [Related]
11. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
[TBL] [Abstract][Full Text] [Related]
12. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
14. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
[TBL] [Abstract][Full Text] [Related]
15. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
[TBL] [Abstract][Full Text] [Related]
16. Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats.
Liu C; Wang L; Zhu R; Liu H; Ma R; Chen B; Li L; Guo Y; Jia Q; Shi S; Zhao D; Mo F; Zhao B; Niu J; Fu M; Orekhov AN; Brömme D; Gao S; Zhang D
Osteoporos Int; 2019 Feb; 30(2):491-505. PubMed ID: 30151623
[TBL] [Abstract][Full Text] [Related]
17. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
[TBL] [Abstract][Full Text] [Related]
19. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
20. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.
Brabnikova-Maresova K; Jarosova K; Pavelka K; Stepan JJ
Arthritis Res Ther; 2014 Oct; 16(5):460. PubMed ID: 25280749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
